Dataset from An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

This open-label, multicenter, randomized Phase III study will investigate the efficacy,
safety, pharmacokinetics and pharmacoeconomics of obinutuzumab (RO5072759, GA101) combined
with bendamustine followed by continued obinutuzumab treatment (maintenance monotherapy)
compared with bendamustine alone treatment in participants with rituximab-refractory indolent
Non-Hodgkin's lymphoma (iNHL). The end of study was defined to when safety follow-up for all
patients had been completed (2 years' safety follow-up from last dose).